Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
Date:3/7/2013

in patients with disease progression following treatment with a first-line, platinum-based chemotherapy doublet regimen.  

OGX-427 Clinical Development Highlights

  • In December 2012, the Company announced the initiation of the Pacific trial, an investigator-sponsored, randomized Phase 2 study evaluating OGX-427 in approximately 80 men with CRPC who are experiencing a rising prostate-specific antigen (PSA) while receiving Zytiga® (abiraterone acetate). The study is currently enrolling at sites in the United States and Canada.
  • The company-sponsored, randomized Phase 2 clinical trial of OGX-427 in combination with gemcitabine and cisplatin in patients with metastatic bladder cancer, Borealis-1, continues to enroll patients throughout the United States, Canada and Europe. The study aims to enroll approximately 180 patients and is expected to complete patient accrual in the second half of 2013.
  • The Company also recently announced plans for the initiation of an investigator-sponsored, randomized Phase 2 study evaluating OGX-427 in patients with advanced or metastatic bladder cancer who have disease progression following initial platinum-based chemotherapy.  The trial, Borealis-2, will seek to enroll approximately 200 patients to receive either OGX-427 plus docetaxel treatment or docetaxel treatment alone and is expected to begin in the first half of 2013.
  • Pacific, Borealis-1 and Borealis-2 are part of the "ORCA" (On-going studies evaluating treatment Resistance in CAncer) program that encompasses clinical studies of OGX-427 across multiple cancer indications. Plans to initiate additional studies as part of the ORCA program will be announced in the coming months.
  • Financial Update and Results

  • Revenue for the fourth quarter and year ended December 31, 2012 increased to
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
    2. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
    3. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
    4. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
    5. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
    6. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
    7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
    8. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
    9. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
    10. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
    11. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... Dec. 24, 2014  Actavis plc (NYSE: ... has received a complete response letter from the ... New Drug Application (NDA) for the fixed-dose combination ... of hypertension.   Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... in the receipt of a complete response letter, ...
    (Date:12/24/2014)... 24, 2014 Soligenix, Inc. (OTCQB: SNGX) ... developing products that address unmet medical needs in ... today that on December 24, 2014 it closed ... The Company raised approximately $2.3 million in gross ... the net proceeds from the offering to fund ...
    (Date:12/24/2014)... N.J. and FARMINGTON, Conn. ... Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company ... of diseases with significant unmet medical need and ... on a private placement of 2,050,000 shares of ... purchase 24,949,325 shares of its common stock.  Funds ...
    Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
    ... , NEW YORK , Jan. 26 ... (NYSE Amex: MGT ), and an industry leader in ... which assists radiologists in the early detection of disease, announces ... further request for Additional Information (AI) letter from the US ...
    ... , CAMBRIDGE, Mass. , ... company, announced today a distribution agreement with OrthoPediatrics Corp., ... sell ETEX,s nanocrystalline calcium phosphate on a non-exclusive basis ... . , (Logo:   http://www.newscom.com/cgi-bin/prnh/20080424/NETH117LOGO ) , ...
    Cached Medicine Technology:Medicsight PLC Receives Additional Information Request for FDA 510(k) Clearance 2Medicsight PLC Receives Additional Information Request for FDA 510(k) Clearance 3ETEX Corporation Announces Distribution Agreement With OrthoPediatrics Corp. 2
    (Date:12/26/2014)... Aliso Viejo, California (PRWEB) December 26, 2014 ... have announced the TransPack Volume 5 Plugin for Final Cut ... to manipulate a hard light tool to pull off an ... Studios. “When users get their hands on TransPack Volume 5, ... TransPack Volume 5 is a set of over 50 Final ...
    (Date:12/26/2014)... Phoenix, AZ (PRWEB) December 26, 2014 ... dependable source for the best in heating, cooling ... demand for 24 hour emergency services in 2014 ... customers alike know that Arizona is known for ... contractor company that understands the intricacies and details ...
    (Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – Forecast and ... landscape, unmet needs, current pipeline and commercial opportunities in ... which is typically used for treating colorectal cancer. It ... gastric cancer and pancreatic cancer. TS-1 is composed of ... approved in 1999 in Japan for the treatment of ...
    (Date:12/25/2014)... The short film “Color of Honor” by young ... a true 9/11 hero, Welles Remy Crowther. It has been ... hours of Nuremberg International Short Film Festival and the 8th ... screenwriter and director Luciana Lagana plays the mother of ... husband, Gregory Graham - Graham plays a heroic ...
    (Date:12/25/2014)... 25, 2014 Recently, LunaDress.co.uk has updated its blog ... related accessories. Now, all of the models at LunaDress.co.uk come with ... groom lifts the wedding veil can turn out to be a ... A wedding veil can always bring surprise to a wedding. On ... how to choose veils for a big day . , ...
    Breaking Medicine News(10 mins):Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2
    ... Ramadoss Friday urged film stars, sportspersons and other celebrities ... interest of public health. ,Addressing the inaugural ... Food Laboratory (CFL) here, he underlined the need for ... the vast population of the country as well as ...
    ... smoking can be deadly. Hence California and Washington laws imposed strict ... years old physically fit suffered from heart problems that led to ... in smoky taverns for 37 years. So the doctors asked him ... that the indoor air pollution levels in bars that allow smoking ...
    ... Department of Energy's Brookhaven National Laboratory and colleagues at ... Center in Italy, and Georgetown University it was found ... more effective treatment. This then could be widely used ... were initially tested on rats and the results of ...
    ... The report of the Mental Health Council of Australia, ... country’s mental health system, the Council //of Australian Governments ... proposed solutions by July. ,However mental health ... lost. The Mental Health Council of Australia launched a ...
    ... who became orphaned after their HIV-infected parents died four ... Government at a function here tomorrow.// ,The ... take care of the children's health, education and welfare, ... P K Sreemati, who at a recent Cabinet meeting ...
    ... of overseas doctors after the July 'sittings', thereby providing ... in the UK., ,'Due to low demand, we ... Part 1 exams outside the UK after the sitting ... the government announced., ,Shiv Pande, Chairman of Indo-British ...
    Cached Medicine News:Health News:Radiation Therapy Made More Compatible 2Health News:Radiation Therapy Made More Compatible 3Health News:Outcry Against Mental Health Institutions 2Health News:Outcry Against Mental Health Institutions 3
    The Stat-Let lines of disposable lancets are all designed with the goals of providing a safe and easy to achieve capillary blood sampling. All of our lancets can be used by most current models of lan...
    Lancets are the fine needles used with a lancing device to draw a blood sample for glucose testing. To make testing less painful, we developed lancets with extra-thin tips....
    The BD Ultra-Fine 33 Lancets are the thinnest lancets available, which means that you'll experience less pain when taking a blood sample....
    For patient-friendly and safe capillary blood collection...
    Medicine Products: